Rating: Neutral (Wait & Verify) | Target Price: RMB 217–241 | Current Price: RMB 227.02 (close on 2026-09-01) | Probability-Weighted Fair Value: ~RMB 218 (-3.9% vs. current) | Margin of Safety: ~-4% | Time Horizon: 12 months
| Item | Last (2026-05-29) | This (2026-09-02) | Driver of Change |
|---|---|---|---|
| Stance | Cautiously bullish | Neutral | After the 20% pullback from RMB 284 to 227, the price has shifted from "slightly below valuation center" to essentially overlapping with this round's baseline fair value (RMB 217–241); margin of safety moved from ~-1% to ~-4%, plus the new H-share dilution overhang |
| Confidence | 0.60 | 0.55 | Quarter-by-quarter slowdown in ex-non-recurring growth (Q1 +21.7% → Q2 ~+17.4%) + widening earnings-noise exposure (fair value + FX + CXMT strategic placement); reduced conviction in direction realization |
| Target price range | RMB 250–310 | RMB 217–241 | ① Total shares rose from ~190 million to 228 million due to full convertible bond conversion (~17% EPS dilution; old target was based on old share count); ② exit multiple anchor changed from 2026E 42–52x to 2027E ex-non-recurring 45–50x (anchored on its own 5-year TTM PE median of 50.5x); ③ sell-side consensus cut 22.3% over the past 90 days |
| Valuation judgment | Fair | Fair | Maintained, as the price remains within the baseline fair range, but the odds shifted from "symmetric, slightly positive" to "symmetric, slightly negative" |
Calibration note: This is a low-divergence judgment (current price deviates less than 1% from the baseline fair center); historically, judgments of this type with "divergence ≤30%" have hit directional calls ~48% of the time — this report assigns no high confidence and positions this as a "verification window," not an action recommendation.
Anji Microelectronics is the undisputed leader in China's CMP slurry market: global share rose from 8% to 13% over three years (company's own calculation based on TECHCET market size), 96.5% of revenue from mainland China, deeply tied to the twin themes of domestic fab capacity expansion and import substitution; 2023–2025 revenue CAGR ~42%, ex-non-recurring ROIC ~15.5%, ROE ≥22% for four consecutive years — quality at the top tier of A-share semiconductor materials. But the current price has fully priced in this quality: the current price implies a 10-year forward ex-non-recurring net profit CAGR of ~19.4% — exactly equal to the actual H1 2026 ex-non-recurring growth rate, leaving no margin of error for deceleration. Moreover, of the headline +41.6% H1 2026 net profit growth, about one-fifth came from fair-value changes in unlisted fund investments; true ex-non-recurring growth was +19.4%, dragged down by unhedged FX losses (RMB 55.13 million). Add the H-share issuance dilution overhang (shareholder approval obtained, filing not yet submitted) and the controlling shareholder's high-price book-build transfer, and the verdict is a great company at a full price: baseline fair value of RMB 217–241 essentially overlaps with the current price, with odds slightly negative-skewed (bear case -42% / bull case +31%). Strategically we stay on the sidelines; verification points are the Q3 report due late October 2026 (whether ex-non-recurring growth can return to ~25% after FX drag fades) and the final H-share issuance terms; if the stock falls below RMB 200 or the terms are digested, the odds will reopen.
Opportunity positioning: The next 6–12 months are a "verification window," not an "action window." The volume logic (share 8%→13%, memory expansion, import substitution) is intact with first-hand evidence, but with price coinciding with baseline fair value, there is no tradable expectation gap.
Priority of upcoming catalysts (ranked by share-price impact):
Expectation gap assessment: A genuine consensus anchor exists (7–16 covering houses over the past 6 months; 10 Buy / 6 Overweight / 0 Sell; median target RMB 278, mean RMB 312, low RMB 202.31), but with two layers of noise: ① most targets feeding the median were published before July (the highest, Goldman Sachs at RMB 509, came when the stock was ~RMB 293); since then consensus has been cut 22.3% and the stock has fallen to RMB 227, so directly citing RMB 278/312 as the "market anchor" is optimistic; ② sell-side EPS is based on the pre-conversion share count, while total shares after conversion are 228.36 million — without adjustment, forward PE is systematically understated by ~20%. Our own 2026E net profit estimate of RMB 1.00–1.08 billion is 7%–16% above the revised consensus (~934 million); if the consensus direction is right (implying H2 2026 net profit of roughly -21% YoY), the baseline fair value would shift lower overall — this is the report's largest self-identified risk exposure.
Key falsification conditions: Single-quarter ex-non-recurring growth <15%; slurry segment gross margin <54%; H-share issuance at a steep discount with heavy dilution; confirmed second-source adoption of Dinglong slurry in memory.
The coexistence of rising share and falling gross margin points to a deliberate choice of "trading new product categories and new customer adoption for scale" (management explanation: dynamic changes in product mix and repositioning of products at different lifecycle stages), rather than pure competitive deterioration; but Dinglong's accelerating volume in slurries/cleaning solutions (especially entry into wafer fabrication with 12-inch fine polishing slurry in May 2026) means post-2027 price competition in mature categories will become more direct. Confidence in this thesis is trimmed from 0.70 to reflect reliance on self-calculated share data and the reversed competitive trajectory.
Wet chemicals' gross margin recovery from ~33% in 2023 to 50%+ validates the platform logic of cross-category reuse of formulation capability; but this battlefield (cleaning/strip/etch solutions) is precisely the open arena where Dinglong's "slurry + cleaning" combo and Jiangfeng, Zhongjuxin, and others are attacking simultaneously; the +51% growth is built on a low base of ~RMB 400 million and cannot be extrapolated into pricing power for the second curve based on the core business's moat.
Excluding the after-tax FX drag (~RMB 46.86 million), H1 ex-non-recurring growth was ~31.9%, matching revenue +33.7% — the "strong headline, lackluster core" pattern is mainly the stacking of FX and fair-value noise lines, not operational deterioration. But it must be faced squarely that earnings-noise exposure is widening, not narrowing: the unlisted fund investments (book value RMB 343 million at period-end) are mark-to-model with no market price anchor and fluctuate both ways, and from July 2026 the market-value swings of the CXMT strategic placement of 18.24 million shares (cost RMB 158 million, lock-up until 2028-01-27) will flow into the fair-value line. Elevated inventory (~84% of half-year revenue) and working-capital absorption from stockpiling are the structural reasons cash flow lags profit.
A balancing note on "no margin of error for deceleration": the reverse DCF reflects the price level's required return, while sell-side earnings expectations (already embedding negative H2 attributable profit growth and a 22.3% 90-day cut) show analysts are already pricing in deceleration — the gap between price and expectations itself suggests the stock may adjust ahead of earnings forecasts. This report's baseline fair value (RMB 217–241) derives from 2027E ex-non-recurring profit of RMB 1.1 billion × 45–50x, with the exit multiple anchored on its own 5-year TTM median of 50.5x and a peer band (Dinglong 70.6x, Jiangfeng 80.3x — both TTMs inflated by non-recurring items); each ±5x on the multiple moves fair value ±RMB 24 — a significant sensitivity. If consensus's negative H2 is confirmed, our own profit estimate 7–16% above consensus becomes a new source of downward revision, dragging baseline fair value lower — this is the core reason for a Neutral rather than cautiously bullish stance.
All four links of the chain (capacity trajectory × unit intensity × localization penetration × company share) have numeric support and the direction holds; residual uncertainty concentrates in: third-party scope differences on China market size exceeding 2x, CXMT installed vs. qualified capacity scope, and memory potentially entering a supply-digestion phase in H2 2027 (tail-end risk of the 18-month window) — a one-quarter slowdown in memory expansion would push materials volume out by a corresponding 2–4 quarters.
Market concerns over the H-share center on discounted issuance and EPS dilution: if issued at 10–15% of post-issue total shares at a 20–30% discount to A-shares (scenario assumption; the company has disclosed no deal numbers), EPS dilution of 10–15% would make the H-share price a psychological anchor for A-shares — one factor in the ~20% pullback since the June announcement (alongside the STAR 50 sector correction and the interim core-earnings quality debate). Counterexamples exist: CATL's H-shares priced essentially at parity with A-shares and drove A-share re-rating post-listing; the 2025–26 A+H wave's discounts are not the statistical median. Moreover, the flip side of the book-build: 21 institutions paid real money at RMB 297.36 (a 31% premium to the current price) two months ago with a 6-month lock-up — demand-side bids have been directly negated by ~24% at the current price; the January 2027 unlock window's absorption is worth tracking.
| Metric (RMB 100 million) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Operating revenue | 12.38 | 18.35 | 25.04 | 15.26 (+33.72%) |
| Net profit attributable to parent | 4.03 | 5.34 | 7.84 | 5.32 (+41.56%) |
| Non-GAAP net profit (ex non-recurring items) | 3.22 | 5.26 | 6.97 | 4.26 (+19.35%) |
| Gross margin | 55.81% | 58.45% | 56.79% | 55.63% (-0.77pp) |
| Net margin attributable to parent | 32.5% | 29.1% | 31.3% | 34.84% |
| Non-GAAP net margin | 26.0% | 28.7% | 27.8% | 27.89% |
| Operating cash flow | 3.36 | 4.93 | 4.40 | 3.20 (+30.68%) |
| Free cash flow (OCF−CapEx) | — | 2.26 | 0.84 | 0.86 |
| Cash + cash-like assets | — | — | — | 17.74 (2026-06-30) |
| Interest-bearing debt | — | — | 11.37 | 5.25 (convertible bonds fully cleared) |
| Debt-to-asset ratio | — | 21.75% | 29.92% | 17.16% |
Reasons for metric changes (line items with YoY ≥±20%, with management explanations):
The volume-driven revenue logic remains intact: 2026H1 revenue was RMB 1.526 billion (+33.72%), of which Q2 alone was RMB 802 million (+34.6% YoY, +10.8% QoQ) — revenue growth accelerated rather than slowed versus Q1 (+32.8%), consistent with the narrative of downstream fab capacity expansion and market share gains. By product, CMP slurries +29.47% (gross margin slightly down at ~55.6%), wet electronic chemicals +51.03% (estimated gross margin ~56%), with the second growth curve's share rising to 20.5%.
Earnings "quality" is the crux of market disagreement: the headline +41.56% attributable profit growth was propped up by RMB 115 million in fair value gains (pre-tax, roughly 20% of attributable profit), while non-GAAP profit grew only +19.35%. Digging deeper, FX losses of RMB 55.1267 million (after-tax drag of ~RMB 46.86 million, or ~11 percentage points of non-GAAP profit) were the single largest drag — excluding this, non-GAAP growth would be ~31.9%, in line with revenue. In other words, the true operating growth rate remains around 30%, but the reported earnings quality is significantly distorted by FX and valuation noise. The market responded with continued share price declines after the interim report, indicating that between "high attributable profit growth" and "fading non-GAAP growth," investors currently choose to believe the latter.
Balance sheet and cash flow: after full conversion of the convertible bonds, interest-bearing debt fell to RMB 525 million and cash-like assets stand at RMB 1.774 billion, for net cash of ~RMB 1.25 billion and a debt-to-asset ratio of 17.16% — a clean balance sheet. OCF of RMB 320 million (+30.7%) still lags profit (OCF/non-GAAP = 0.75) but is improving in direction; the further 22.7% inventory increase and the RMB 1.288 billion balance represent the largest impairment risk exposure (the company calls it strategic safety stock). CapEx +89% reflects accelerated capacity expansion (Shanghai base ramping up in 2028, plus the Ningbo 20,000-ton project), with depreciation pressure set to rise over the next two years.
Management communication: in its 2025 annual report, the company gave only a qualitative operating plan for 2026 (five points, no quantitative guidance) and issued no earnings pre-announcement with the interim report — the company has no tradition of quantitative guidance, so investors can only verify indirectly via quarterly product-level data, which amplifies the market's volatility around single-quarter results.
Business model: a formulary semiconductor materials manufacturer — using abrasive particles (colloidal silica, fumed silica, cerium oxide) and high-purity chemicals as raw materials, products are developed by formulation, blended and compounded, filtered and filled, then sold directly to wafer fabs. Three structural features: ① Consumable repeat purchases: CMP slurries are continuously consumed in wafer production, making revenue recurring (consignment/settlement-at-use models account for 65.83% of revenue, with strong customer stickiness); ② Asset-light with high gross margins: production is mainly compounding, with blended gross margin at 55-58%, significantly higher than peers such as sputtering targets (JX Metal's ~17% net margin) and silicon wafers (NSIG running losses); ③ R&D-heavy: R&D expense ratio of ~16-18%, with R&D personnel exceeding 50% of staff.
Cash content of earnings: OCF/net profit for 2023-2026H1 was 0.83 → 0.92 → 0.56 → 0.60 (attributable basis; non-GAAP basis 0.75 for 2026H1), below the 0.7 threshold for two consecutive periods; FCF/net profit for 2024-2026H1 was 0.42 → 0.11 → 0.16 — the bulk of book profit is either tied up in inventory (stockpiling) or swallowed by capacity expansion (CapEx). Under this report's framework, it must be stated explicitly: this company is currently in a stage of "high profit growth but little cash available to shareholders". If, after the CapEx peak of 2027-2028 (Shanghai base ramp-up), OCF/net profit still fails to return above 0.8, its earnings quality needs to be reassessed.
Recurring earnings test: in 2026H1, non-recurring gains/losses (after-tax net) of RMB 106 million accounted for 19.9% of attributable profit, exceeding the 15% threshold — headline attributable growth (+41.6%) significantly outpaced non-GAAP growth (+19.4%), and the bulk of fair value gains comes from mark-to-model valuations of unlisted funds (no market price anchor, reversible). For full-year 2025, non-recurring gains were RMB 87.09 million (fair value 69.69 million + government grants 35.97 million), or 11.1% of attributable profit — the non-recurring share is expanding, an unfavorable trend.
Return on capital: FY2025 non-GAAP ROIC was ~15.5% (NOPAT ~RMB 720 million ÷ invested capital ~RMB 4.67 billion), about 6 percentage points above WACC (9.5%), in the "real growth" range (>15% is a strong signal); weighted ROE was 25.18% (including leverage contribution before the convertible bond conversion; post-conversion leverage has declined, with the debt-to-asset ratio at only 17.2% by end of 2026H1 — future headline ROE will be suppressed by dilution from the enlarged share count).
Maintenance CapEx: CapEx/depreciation for 2024-2026H1 was 1.70 → 1.85 → 2.07 (annualized), rising continuously and above 1.5 — the company is in a capacity expansion cycle (Ningbo and Shanghai bases), so CapEx is "growth expenditure" rather than purely maintenance, but an intensity above 2x means depreciation will rise rapidly over the next two years; the test is whether this ratio falls back below 1.5 after the 2028 ramp-up.
Moat and red flags: the moat is real (full-suite slurry portfolio + 2-3-year customer qualification cycles locking in customers + vertical integration via in-house cerium oxide abrasives); the red flags are also real — customer concentration (top five 71.48%, largest 26.62%, second 26.41%, though slowly declining from 80.5% in 2023), an unhedged net USD exposure of RMB 1.797 billion, and a payout ratio of only ~11% (the bulk of profit reinvested).
Consistency of words and actions: pragmatic, leaning conservative. The company has no tradition of quantitative guidance (operating plans in recent annual reports have all been qualitative). Verifiable commitment-delivery pairs: ① the 2024 annual report promised plating solutions "development and validation proceeding as planned" → in 2025, Damascene plating solutions entered mass-production sales on schedule (delivered); ② the convertible-bond-funded projects (Shanghai base / Ningbo 20,000 tons) stood at 61.89% investment progress as of 2026H1 (Shanghai base 42.4%), consistent with the prospectus schedule (on track); ③ market share statements delivered three years running (8% → 11% → 13%, self-calculated). Verdict: pragmatic, but note that its share figures are self-calculated and it has never given a quantitative explanation for the gross margin decline.
Shareholder friendliness: neutral, leaning issuer-friendly. Payout ratios for FY2023-2025 were 8.6% / 10.9% / 11.2% (RMB 0.35/0.45/0.50 per share), plus two 10-for-3 bonus issues; no cancel-based buybacks (the 2024 buyback was for equity incentives). A dense financing history: a simplified private placement of RMB 207 million in 2023, convertible bonds of RMB 831 million in 2025 (fully converted in March 2026, ~3.8% dilution), and a planned H-share listing in June 2026 — continuous equity financing combined with low dividends means shareholder returns rely mainly on "growth retention," with limited direct returns to secondary-market shareholders.
Risk signals: ① the controlling shareholder sold 1.27% via an inquiry-based transfer in July 2026, cashing out RMB 862 million (RMB 297.36/share), overlapping with the H-share planning window — a compliant liquidity-activation move, but a negative timing signal; ② the directors/supervisors/executives' share reduction plan was renewed as scheduled upon its June expiry, with ~RMB 8.12 million executed in July (immaterial in size, but the "renewal" itself sends a marginal signal); ③ Chair Wang Shumin sold 29,100 shares in July at RMB 278.76. With management and major shareholders collectively selling above RMB 297 while social security funds added in Q2, industrial capital and allocation capital diverge in direction at current levels.
| Segment | 2026H1 revenue | Share | YoY | Gross margin (basis) | Business logic in one line |
|---|---|---|---|---|---|
| CMP slurries | RMB 1.204 bn | 78.9% | +29.47% | ~55.6% (back-calculated; FY2025 disclosed 58.28%) | Full-suite CMP slurries (copper/barrier, tungsten, cerium oxide, dielectric, TSV), 13% global share (self-calculated), core cash cow |
| Functional wet electronic chemicals | RMB 313 mn | 20.5% | +51.03% | ~56% (back-calculated; FY2025 disclosed 50.00%) | Post-etch/post-CMP cleaning solutions, etc.; second growth curve, gross margin recovered from ~33% to 50%+ over three years |
| Others (incl. plating solutions) | ~RMB 9 mn | <1% | — | ~45% (FY2025) | Damascene plating solutions entered mass production in 2025 and hit key milestones in 2026H1; revenue not separately disclosed |
Profit driver: slurries contribute ~79% of revenue and ~79% of gross profit (12.04 × 55.6% ≈ RMB 670 million vs wet chemicals 3.13 × 56% ≈ RMB 175 million) — the segment structure of profit is highly aligned with that of revenue; slurries are the absolute mainstay, while wet chemicals are the growth engine rather than the profit engine. Gross margins across the two segments have converged (~55-56%), with the gap under 1pp (not significant on a back-calculated basis), a marked narrowing from FY2025 (58.3% vs 50.0%, an 8.3pp gap) — the second curve's profitability is converging toward the core business, the strongest data support for the platform thesis. The risk is equally clear: slurry gross margin has declined year by year from 61.16% in FY2024 to 55.6% (cumulative -5.6pp), as the combined pressure of annual price cuts on mature products and pricing concessions for new product introductions continues to play out.
Accounting red flags:
Cross-period consistency:
Current market data (close of 2026-09-01): share price RMB 227.02, market cap RMB 51.8 billion. PE(TTM) 55.2x (80th percentile over the past 3 years / 56th percentile over the past 5 years; 5-year median 50.5x); adjusted (ex-non-recurring) TTM 67.7x; PB 10.7x (75th percentile over 3 years); PS(TTM) 17.9x. Earnings include roughly 20% non-recurring noise and the company is in a high-growth investment phase, so mechanical percentiles are for reference only — the primary anchor uses forward multiples: 2026E consensus attributable earnings 55.5x, 2027E 42.9x (after convertible-bond dilution adjustment); PEG approx. 1.5 (consensus 42.9x ÷ 2027E growth 29.3%).
Peer comparison (TTM, as of 2026-09-01):
| Company | PE(TTM) | PB | 2026H1 Revenue Growth | ROE | Notes |
|---|---|---|---|---|---|
| Anji Technology | 55.2x (ex-non-recurring 67.7x) | 10.7 | +33.7% | 25.1% (FY2025 weighted) | Ex-non-recurring net margin 27.9%, highest earnings quality in the sector |
| Dinglong | 70.6x | 11.8 | +11.2% (CMP segment +63%) | 14.8% (FY2025) | No.1 in polishing pads, market cap RMB 66.2 bn has overtaken Anji |
| KFMI (Jiangfeng Electronics) | 80.3x | 8.7 | +30.7% | approx. 18% (annualized) | TTM includes substantial non-recurring items; true multiple is higher |
| NSIG | Loss-making | 4.1 | +36.5% (attributable net loss of -965 mn) | Negative | Silicon wafer price war; same track, different business |
| SW Electronics Chemicals III median | 99.4x | 6.4 | Net profit growth median +11.4% | 5.8% | Anji PE at 13th percentile, ROE at 100th percentile |
Market-implied expectations: reverse DCF shows the current price (EV RMB 50.6 bn) requires an ex-non-recurring CAGR of approx. 19.4% over the next 10 years, equivalent to 54.4x EV/E on normalized earnings. Against reality: ex-non-recurring growth 2024 +63% → 2025 +32% → 2026H1 +19.4% (approx. +31.9% excluding FX), with no change in the slope of market-share gains on the revenue side — the current price requires the company to sustain, unchanged for ten years, its latest half-year ex-non-recurring growth rate (the FX-suppressed figure). Relatively speaking, the current price is not a bubble (implied 19.4% < sell-side 2027E path of +29%), but if growth keeps stepping down quarter by quarter, the current price leaves no margin for error.
Three-layer value (EPV):
Three scenarios and odds (12 months; exit anchor is 2027E ex-non-recurring earnings × exit multiple):
| Scenario | Probability | Fair Value Range | Key Swing Factor | vs. Current Price |
|---|---|---|---|---|
| Bear | 25% | RMB 125–137 | Ex-non-recurring growth falls below 15% (Dinglong encroachment + utilization swings + continued FX losses) → 2027E ex-non-recurring RMB 940–970 mn × 33-35x (lower bound of sector de-rating), plus approx. 8% H-share dilution | -42% (midpoint RMB 131) |
| Base | 55% | RMB 217–241 | Ex-non-recurring growth holds around 25% (2026E ex-non-recurring RMB 850–920 mn → 2027E approx. RMB 1.1 bn) × 45-50x (own 5-year median 50.5x converted to forward basis) | +1% (midpoint RMB 229) |
| Bull | 20% | RMB 284–310 | Storage expansion + share jump in advanced nodes → 2027E ex-non-recurring RMB 1.18–1.22 bn, 2028E RMB 1.4 bn+ path visible × 55-58x (ramp-phase precedent multiples: Dinglong 60x+ during its 2019-21 volume ramp; lower bound of own 10-year central 65x) | +31% (midpoint RMB 297) |
Probability-weighted fair value approx. RMB 218, -3.9% vs. current price — the odds skew slightly negative. The bear case already covers the most pessimistic published forecasts (lowest sell-side target price RMB 202.31, implying approx. 38x 2027E): this report's bear-case midpoint of RMB 131 is below that value, because the bear case additionally combines H-share high-discount dilution with ex-non-recurring growth falling below 15% — a tail scenario more cautious than the current most-pessimistic sell side; the base range (217-241) sits between the most pessimistic market view (202.31) and the most optimistic (Goldman Sachs 509, issued when the stock was at 293 and already partly repudiated by the market) — the anchor is within bounds.
In-house earnings forecast (reconciliation anchor):
| Period | Revenue | Attributable Net Profit | Ex-non-recurring Net Profit | Key Drivers |
|---|---|---|---|---|
| 2026E | RMB 3.30–3.37 bn (+32-35%) | RMB 1.00–1.08 bn | RMB 850–920 mn (+22-32%) | H1 has locked in the lower bound; new production line ramp; gross margin 55.5-56.5% flat; neutral FX assumption for H2 |
| 2027E | RMB 4.2–4.4 bn (+27-31%) | RMB 1.22–1.34 bn | RMB 1.08–1.18 bn (+25-30%) | China capacity expansion + share 13%→14-15%; wet chemicals + electroplating solution second curves; gross margin 55-57% |
Our attributable forecast is 7-16% above the revised-down consensus (RMB 934 mn) — the point of divergence is H2: consensus implies H2 attributable net profit of approx. -21% YoY, whereas this report believes that with capacity ramp and no repeat FX losses, H2 ex-non-recurring earnings should grow +20% or more YoY. If the Q3 report proves consensus right, this forecast will be revised down and the base-case fair value will fall accordingly; otherwise, a positive expectation gap opens up.
Conclusion: fairly valued, target price range RMB 217–241 (base-case fair value); excellent quality coexists with a full price. The current price carries a premium of approx. 4.4% over the base-case fair value floor (safety margin approx. -4%, no effective discount) and approx. +6.2% upside to the ceiling; downside to the bear-case ceiling of RMB 137 is -39.7% — the odds skew slightly negative on both sides, consistent with the "Neutral/Wait-and-See" rating. Anchoring for the base-case exit multiple of 45-50x: own 5-year TTM PE median 50.5x (historical actual) converted to a forward basis; peers Dinglong 70.6x / KFMI 80.3x as upper references (inflated by non-recurring items); deviations from the anchor require justification — the bull case's 55-58x borrows precedent multiples from a "volume-ramp phase," as noted.
1. Quantified chain from industry size to demand inflection
Anji Technology operates in process chemicals for IC manufacturing, core products being CMP slurries (approx. 79% of revenue), functional wet electronic chemicals (20.5%), and electroplating solutions (<1%).
Global figures (TECHCET, cited via company annual report): global semiconductor CMP materials (slurries + pads) at USD 3.800 bn in 2025, with slurries accounting for nearly 60% (approx. USD 2.28 bn; CIC's estimate approx. USD 2.4 bn — the two consultancies' figures are close); 2026E +10.3% to USD 4.2 bn; 2025-2030 CAGR 8.8%. Parallel figures: global semiconductor wet chemicals USD 5.440 bn in 2025 (+6%, 2024-2029 CAGR approx. 6%); global electroplating chemicals USD 1.381 bn in 2025 (+9.3%, 2024-2029 CAGR 7.7%). A wider frame: SEMI's global wafer fab materials at approx. USD 70 bn in 2025, of which mainland China approx. USD 15 bn.
China figures (compiled by Analysys/AskCI, sourced from Dinglong's prospectus / Frost & Sullivan): China's CMP materials market approx. RMB 8.2 bn in 2025 → over RMB 10 bn by 2027 → RMB 17.6 bn by 2030, CAGR 16.5%, roughly twice the global growth rate. Conflicting figures must be presented side by side: Frost & Sullivan estimates for the China market are systematically optimistic — its implied global CMP materials size (approx. USD 5 bn scale) is about 30% higher than TECHCET's USD 3.8 bn, and third-party estimates of China's slurry sub-segment vary by more than 2x (from approx. RMB 2.7 bn to approx. RMB 6 bn in 2024, mainly due to whether storage-expansion volumes and category breadth are included). This report uses TECHCET's global figure as the baseline and Frost & Sullivan's China figure as the upper-bound scenario.
Quantified chain of the demand inflection (one of this report's core judgments): Anji's demand is being repriced by three exogenous forces, with every link of the four-link chain supported by numbers —
2. Value chain and value distribution
Upstream: abrasive particles/nano-abrasives (colloidal silica, fumed silica, cerium oxide) + high-purity chemicals. Abrasives accounted for approx. 54.6% of Anji's total slurry costs in 2023, with direct materials at 76.57% of slurry COGS; the top five suppliers account for 49.93% of total purchases and the largest single supplier 20.46% — upstream is concentrated and partly import-dependent, leaving the company with weak bargaining power upstream. Midstream (where the company sits): formulation-blending-filling, know-how intensive, asset-light, high margin — value-chain gross margin is mainly captured in the midstream formulation step (Anji's blended gross margin approx. 56%, vs. global losses in the wafer segment). Downstream: wafer fabs (top five customers at 71.48%, two main customers at approx. 26% each) and advanced packaging houses. Anji's vertically integrated positioning (in-house cerium oxide abrasives at scale, JV colloidal silica line with Shandong Ante) simultaneously solves three problems: cost (abrasives are over half of costs), supply security (avoiding upstream export controls), and performance customization — this is the structural source of its gross margin resilience.
3. Supply-demand and competitive structure
Supply side: formulation-based blending capacity expands quickly, total supply is ample — the real bottleneck is "validated capacity": loose at the low-mid end, tight at the high end (qualified supply of tungsten, cerium oxide, metal gate, and advanced packaging TSV/hybrid bonding slurries is scarce). Concentration (China CMP materials market 2025, AskCI/Dinglong prospectus basis): CR5 approx. 71.5% — Anji No.1 at 22.5%, Qnity No.2 at 18.2%, Dinglong No.3 at 16.8%; the two domestic players combined at 39.3% have overtaken the three overseas players combined at 32.2%; Anji's share has for the first time surpassed the US platform giant in the sub-segment, marking the entry of import substitution into a "share swap" phase. Global slurry landscape: Entegris (incl. CMC/Cabot businesses) largest (third-party estimate approx. 20%, including pads, to be verified), with Fujimi, Resonac, Merck, and Anji (13%) forming the mainstream camp. Entry barriers: 2-3 year per-customer, per-process-step qualification cycles + formulation patents (Anji's R&D expense ratio approx. 17.8%, R&D staff 52.1% of headcount) + upstream abrasive preparation technology + stickiness of on-line settlement channels. Competitive intensity: price competition has emerged in mature categories (Anji slurry gross margin -5.6pp over two years); Dinglong is extending from pads into slurries/cleaning solutions (2026H1 RMB 193 mn, +63%, with large-wafer fine-polish slurries already in 12-inch wafer manufacturing) — its overlap with Anji will widen, though the current scale gap is still approx. 10x; advanced nodes and new categories remain a technology race rather than a price war. Substitution threat is low: CMP is an essential step for planarization in chips with 20+ interconnect layers, and new structures add net demand.
4. Cycle and regulation
The industry is in an upcycle overlaid with mid-stage growth: WSTS global semiconductor market at USD 795.6 bn in 2025 (+26.2%), with SEMI projecting global sales to break USD 1 tn by end-2026; 300mm fab equipment spending +18% in 2026, +14% in 2027; storage is in a strong upcycle, with third parties flagging a possible peak in H2 2027. Leading indicators: fab equipment spending and utilization, storage makers' capex, materials makers' shipments/inventories, slope of localization rates, and Anji's annual global share gains. Regulation: (1) the US BIS penetration rule auto-reinstates on 2026-11-10 (unless China-US extension) — a binary event; reinstatement strengthens the domestic qualification narrative (Anji relatively benefits) but suppresses sector risk appetite; (2) Big Fund Phase III at RMB 344 bn, approx. 70% directed to equipment and materials localization, deployment accelerating since July; (3) the "Plan for High-Quality Development of the Electronic Chemicals Industry" targets 40% localization by 2026. Policy direction is broadly favorable; residual risk lies in imported upstream abrasives (the company has hedged with in-house abrasives).
5. Peer comparison
| Company | 2025 Revenue | 2026H1 Growth | Gross Margin | ROE | Positioning and Differentiation |
|---|---|---|---|---|---|
| Anji Technology | RMB 2.504 bn (+36.5%) | +33.7% | 55.6% | 25.1% (FY2025 weighted) | Slurry formulation leader, highest earnings quality in the sector |
| Dinglong | RMB 3.660 bn (+9.7%) | +11.2% (CMP segment +63%) | N/A (H1 overall 58.8%) | 14.8% (FY2025) | No.1 in pads (capital-intensive full-process), extending into liquids; more complementary than competitive with Anji, but overlap widening |
| KFMI (Jiangfeng Electronics) | RMB 4.604 bn (+27.7%) | +30.7% | N/A | approx. 18% (annualized) | Sputtering targets leader, larger scale but low net margin (ex-non-recurring net margin approx. 7.5% vs. Anji 27.9%) |
| NSIG | RMB 3.716 bn (+9.7%) | +36.5% (attributable net loss -965 mn) | -17.1% (2025) | Negative | 300mm wafer leader, capital-intensive + deep losses in global price war — a counterexample showing "semiconductor materials ≠ homogeneous prosperity" |
6. Company positioning within the industry
China market leader + head of the global second tier: global share 13% (company's own basis) still trails Entegris, but the gap narrows by approx. 2pp per year; No.1 in China CMP materials at 22.5%, having overtaken Qnity by 4.3pp. Share trend is upward (2025 slurry sales volume +35.9%, 2026H1 revenue +33.7%). Moat: full-category matrix + formulation know-how + vertical integration into in-house abrasives + validation lock-in. Share definitional caveat: the company computes its global share (13%) against TECHCET's published market size; independent estimate approx. 12%; "No.1 in China CMP materials at 22.5%" is on the AskCI/Dinglong prospectus basis (including pads); "China slurry share 40%+" is this report's estimate — the three figures differ in category coverage and timing; any single figure must be cited with its definition.
The defining dimension distinguishing semiconductor materials from generic chemicals/growth stocks is the dual lock that wafer-fab qualification cycles place on both revenue cadence and competitive structure. This has direct implications for the investment judgment on Anji:
Qualification as a barrier: slurry formulations must be qualified customer by customer and process step by process step, taking 2-3 years; the same technology node requires different formulations at different fabs, and switching suppliers entails yield risk on production lines — this determines: (1) the recurring, sticky nature of existing-customer revenue (on-line settlement at 65.83%); (2) new entrants (including Dinglong) can only ramp gradually, not abruptly; (3) Anji's expansion into new customers/new categories equally takes time, giving revenue predictability above typical manufacturing.
Qualification cycles are being compressed by external forces: under normal commercial conditions, qualification takes 2-3 years; under the threat of the Entity List and the penetration rule, domestic fabs are proactively shortening introduction cycles for local materials for supply-chain security — the tighter the restrictions, the faster the domestic qualification. This constitutes Anji's "geopolitical policy option": escalation hits sector sentiment short term but accelerates share transfer medium term. Whether the penetration rule is reinstated on 2026-11-10 is the next checkpoint.
The deep structure of import substitution: slurry localization for mature processes has exceeded 30% (supply-side competition will intensify and annual price-down pressure will become explicit), while localization for advanced nodes (14nm and below) remains in low single digits to low double digits — Anji's share elasticity lies mainly in advanced nodes and new storage capacity, which is precisely the industry basis for gross margin pressure (mature end) coexisting with high revenue growth (advanced end + new capacity). Leading indicators for the pace of import substitution: local materials' share in domestic fab tenders, the match between Anji's product-line revenue growth and industry capacity deployment, and the density of announcements on qualification breakthroughs by Dinglong, KFMI, and peers.
Monopsony price-down culture: wafer fabs (especially the two storage giants) enforce annual price reductions on materials, and domestic slurry prices are already 20-30% below imports — "market doubling" is in value terms; volume doubling does not equal revenue doubling, let alone profit doubling; sustaining unit economics depends on in-house abrasive cost reduction and mix upgrade toward advanced categories as offsets — this is the core variable determining whether Anji's 55% gross margin can hold.
Overall Rating: Neutral (Wait-and-See), Confidence 0.55, Time Horizon 12 months. Anji Microelectronics' quality ranks in the top tier of the A-share semiconductor materials sector (ROE at the 100th percentile, non-GAAP net margin of 27.9%, net cash position, steadily rising global market share, and quantitatively confirmed inflection point in industry demand). However, the current price of 227.02 yuan overlaps with the baseline fair value range of 217–241 yuan; the market has already priced the latest half-year growth rate as the norm for the next decade. Combined with the overhang from potential H-share dilution and widening earnings noise, the risk-reward symmetry is slightly skewed to the downside. Answer "is it cheap?" and "is it good?" separately: not cheap, not expensive; very good, but already fully paid for.
Strategy: Existing holders may continue holding, using the bear-case ceiling of 137 yuan / baseline floor of 217 yuan as a risk-budget reference. Investors without positions should wait for two types of reassessment signals: ① price falling below 200 yuan (corresponding to sub-40x 2027E non-GAAP earnings, turning the odds positive); or ② H-share terms being finalized (discount ≤15% with restrained size), or Q3 non-GAAP earnings growth returning to around 25% (refuting quality concerns).
Risk and Catalyst Alerts (formal wording, for tracking purposes):
Upside catalysts: September 10 STAR Market semiconductor group earnings briefing (public communication window for the H-share timetable and full-year outlook); late-October Q3 report (quarterly non-GAAP growth rebound due to FX base effects); memory capacity expansion milestones (CXMT year-end capacity, YMTC Phase III ramp-up); H-share filing and pricing finalization (moderate terms would clear the overhang); Big Fund III directing investment toward materials (unconfirmed); sector ETF fund inflows returning.
Downside risks: quarterly non-GAAP growth falling below 15%; H-share issuance at a steep discount (>25%) with heavy dilution (≥10%); Dinglong's entry as second source in memory confirmed; continued RMB appreciation causing further FX losses (unhedged exposure of 1.797 billion yuan); memory entering a supply digestion phase in 2027; sector sentiment shock from BIS penetration rule reinstatement on 2026-11-10; lock-up expiry for transferee institutions from the January 2027 inquiry-based transfer; inventory write-downs.
Key Source Citations: Anji Microelectronics 2026 Interim Report (2026-08-27), FY2025 Annual Report (2026-04-16), H-share planning advisory announcement (2026-06-17), inquiry-based transfer verification report (2026-07-07), registered capital change announcement (2026-08-27), investor Q&A (2026-08-10); TECHCET/SEMI/WSTS (as cited via company annual reports and financial media), E-lead Research (citing Dinglong's prospectus), Securities Times/CLS/Xinhua Finance (Dinglong interim report, CXMT IPO, Hua Hong capital increase), Investing.com sell-side target price compilation, Capital Securities commentary (2026-08-27). The earnings forecasts and valuation estimates in this report are independent calculations, with methodologies and assumptions noted in the main text.